Latest Funding News

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

AIMS Property Securities Fund (APW) reported a remarkable financial year ending June 2025, with net income and revenue more than doubling and net tangible assets per unit rising 31.8%. The fund’s conservative, debt-free approach and diversified portfolio helped it outperform the broader market despite ongoing distribution suspensions.

Yojee Limited reported a 34% revenue decline to $675k and a 29% reduction in net loss to $6.02 million for FY2025, reflecting a strategic pivot and accelerated development of its MOSAIC freight forwarding platform. The company raised $8.9 million to fund growth and platform commercialization.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Synertec Corporation Limited reported an 8% revenue decline to $18.2 million in FY2025 alongside a $7.64 million net loss, yet its Engineering segment showed a strong EBITDA rebound and its Powerhouse renewable technology revenue nearly doubled.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Finexia Financial Group has restated its FY24 financials due to a material error in expense accruals and reduced the value of its Stayco investment by $4 million following an external valuation review.

Spenda Limited reported a 106% surge in revenue to $11.1 million for FY25, driven by acquisitions and expanded services, yet posted a substantial $24.3 million net loss largely due to goodwill impairment. The company’s strategic moves and funding needs highlight a pivotal phase ahead.

Beonic Ltd reported a significantly reduced net loss of $3.17 million for FY2025, alongside improved margins and EBITDA profitability, underpinned by a major North African airport contract and a $4.18 million convertible note raise to accelerate growth.

Genmin Limited has increased insider loans by A$0.5 million, reinforcing funding for its flagship Baniaka iron ore project in Gabon as it targets production in late 2026.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.